Evidence map›Paper›PMID 39338373›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model.

Sydney Relouw, George J Dugbartey, Patrick McLeod, Natasha N Knier, Francisco Martinez Santiesteban, Paula J Foster, Heather-Anne Cadieux-Pitre, Nicole M Hague, Jenna Caine, Kaitlin Belletti and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sydney RelouwDepartment of Microbiology & Immunology, Western University, London, ON N6A 5C1, Canada.
George J DugbarteyMatthew Mailing Center for Translational Transplant Studies, Western University, London Health Sciences Center, London, ON N6A 5A5, Canada.ORCID 0000-0001-8161-7202
Patrick McLeodMatthew Mailing Center for Translational Transplant Studies, Western University, London Health Sciences Center, London, ON N6A 5A5, Canada.ORCID 0009-0004-6141-5098
Natasha N KnierDepartment of Medical Biophysics, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0002-4960-6535
Francisco Martinez SantiestebanDepartment of Medical Biophysics, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0001-6623-8423
Paula J FosterDepartment of Medical Biophysics, Western University, London, ON N6A 5C1, Canada.
Heather-Anne Cadieux-PitreDepartment of Animal Care & Veterinary Services, Western University, London, ON N6A 5C1, Canada.
Nicole M HagueDepartment of Animal Care & Veterinary Services, Western University, London, ON N6A 5C1, Canada.
Jenna CaineDepartment of Animal Care & Veterinary Services, Western University, London, ON N6A 5C1, Canada.
Kaitlin BellettiDepartment of Animal Care & Veterinary Services, Western University, London, ON N6A 5C1, Canada.
Sally MajorMatthew Mailing Center for Translational Transplant Studies, Western University, London Health Sciences Center, London, ON N6A 5A5, Canada.
Caroline O'NeilRobarts Research Institute, Western University, London, ON N6A 3K7, Canada.ORCID 0009-0004-3775-1948
Manal Y GabrilDepartment of Pathology and Laboratory Medicine, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0002-4133-992X
Madeleine MoussaDepartment of Pathology and Laboratory Medicine, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0003-4786-6226
Melissa J HuynhDepartment of Surgery, Western University, London, ON N6A 5C1, Canada.
S M Mansour HaeryfarDepartment of Microbiology & Immunology, Western University, London, ON N6A 5C1, Canada.ORCID 0000-0002-1125-8176
Alp SenerDepartment of Microbiology & Immunology, Western University, London, ON N6A 5C1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Present bladder cancer therapies have relatively limited therapeutic impact and account for one of the highest lifetime treatment costs per patient. Therefore, there is an urgent need to explore novel and optimized treatment strategies. The present study investigated the effects of inhibiting endogenous hydrogen sulfide (H

Indexed as

apoptosisbladder cancer (BC)cystathionine γ-lyase (CSE)gemcitabinehydrogen sulfide (H2S)intravesical administrationmagnetic resonance imagingpropargylglycine (PAG)tumor progression

Identifiers

PMID39338373
PMCPMC11435360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.